In the Phase III IMvigor011 trial, Natera’s Signatera circulating tumor DNA (ctDNA) test successfully stratified muscle-invasive bladder cancer patients regarding response to Genentech's Tecentriq (atezolizumab) adjuvant therapy. Patients positive for minimal residual disease detected by Signatera showed statistically significant improvements in disease-free and overall survival with treatment compared to placebo. These promising results underpin Natera's pending FDA companion diagnostic submission, potentially enabling personalized post-cystectomy treatment decisions for bladder cancer patients.